3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
13
Breast Neoplasms
12
Colorectal Neoplasms
11
Ovarian Neoplasms
10
Recurrence
9
Neoplasms
9
Small Cell Lung Carcinoma
8
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, Large B-Cell, Diffuse
7
Prostatic Neoplasms
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Carcinoma
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Recurrent Squamous Cell Lung Carcinoma
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Mesothelioma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Kidney Neoplasms
3
Interventions
Carboplatin
25
Bevacizumab
18
Paclitaxel
17
Pemetrexed
16
Erlotinib Hydrochloride
14
Radiotherapy
12
Docetaxel
9
Gemcitabine
7
Cisplatin
6
ceritinib
5
Taxes
5
Cetuximab
5
pembrolizumab
3
pegfilgrastim
3
capmatinib
3
Surgical Procedures, Operative
3
Radiosurgery
3
Metformin
3
Gefitinib
3
Cyclophosphamide
3
Thalidomide
2
Sorafenib
2
Radiotherapy, Conformal
2
Nivolumab
2
Immunoglobulin G
2
Filgrastim
2
Disulfides
2
Albumin-Bound Paclitaxel
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Adenocarcinoma of Lung
×
durvalumab
×
Clear all
No trials found.